Literature DB >> 16926650

Interstitial lung disease in rheumatoid arthritis: recent advances.

Dong Soon Kim1.   

Abstract

PURPOSE OF REVIEW: Subsequent to the ATS/ERS consensus classification of idiopathic interstitial pneumonia, non-specific interstitial pneumonia pattern was the dominant pattern in many collagen vascular diseases, which may explain the better prognosis of interstitial pneumonia associated with collagen disease than idiopathic pulmonary fibrosis. Recent papers on rheumatoid arthritis suggest that this is not the same in all collagen diseases, and this paper will review previous data and discuss recent papers. RECENT
FINDINGS: In contrast to other collagen diseases, the usual interstitial pneumonia pattern seems to be more common, or at least as common in rheumatoid arthritis. This pathological observation was supported by high-resolution computed tomography findings. In addition to the usual interstitial pneumonia pattern, several types of small airway involvements were frequently observed in rheumatoid arthritis-associated interstitial pneumonia, the prognosis of which is also variable.
SUMMARY: Because the usual interstitial pneumonia pattern may be more frequent in rheumatoid arthritis and some data suggest a poor prognosis for rheumatoid arthritis-associated interstitial pneumonia, further studies are required on the prognosis of collagen vascular disease-associated interstitial pneumonia, especially in relation to the pathological pattern. Drug-related interstitial pneumonia should also be considered in rheumatoid arthritis patients on methotrexate or newer drugs such as leflunomide.

Entities:  

Mesh:

Year:  2006        PMID: 16926650     DOI: 10.1097/01.mcp.0000239552.55326.ee

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  13 in total

1.  Lipid-derived free radical production in superantigen-induced interstitial pneumonia.

Authors:  Hisako Miyakawa; Ronald P Mason; Jinjie Jiang; Maria B Kadiiska
Journal:  Free Radic Biol Med       Date:  2009-04-17       Impact factor: 7.376

Review 2.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

3.  Respiratory symptoms in rheumatoid arthritis: relation to pulmonary abnormalities detected by high-resolution CT and pulmonary functional testing.

Authors:  Amir A Youssef; Shereen A Machaly; Mohammed E El-Dosoky; Nermeen M El-Maghraby
Journal:  Rheumatol Int       Date:  2011-04-03       Impact factor: 2.631

4.  Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis.

Authors:  Dam Kim; Soo-Kyung Cho; Chan-Bum Choi; Jung-Yoon Choe; Won Tae Chung; Seung-Jae Hong; Jae-Bum Jun; Young Ok Jung; Tae-Hwan Kim; Tae-Jong Kim; Hye-Soon Lee; Joo-Hyun Lee; Jisoo Lee; Shin-Seok Lee; Dae-Hyun Yoo; Bo Young Yoon; Jin Woo Song; Sang-Cheol Bae; Yoon-Kyoung Sung
Journal:  Rheumatol Int       Date:  2017-07-26       Impact factor: 2.631

5.  Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Elizabeth F Redente; Martin A Aguilar; Bart P Black; Benjamin L Edelman; Ali N Bahadur; Stephen M Humphries; David A Lynch; Lutz Wollin; David W H Riches
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

6.  Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.

Authors:  L Zhao; K Xiao; H Wang; Z Wang; L Sun; F Zhang; X Zhang; F Tang; W He
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

7.  Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis.

Authors:  Andrew J K Ostör
Journal:  Clin Rheumatol       Date:  2008-08-01       Impact factor: 2.980

8.  Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

Review 9.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

10.  Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis.

Authors:  Silvia A Quadrelli; Luciana Molinari; Lorena M Ciallella; Martin Bosio; Alejandro Salvado
Journal:  Rheumatol Int       Date:  2009-01-08       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.